Image

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Trial testing CAR T therapy for difficult multiple myeloma cases.

Recruiting
18 years and older
All
Phase 1/2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study explores GC012F (also known as AZD0120), a new CAR T-cell therapy for adults with relapsed/refractory Multiple Myeloma, a type of blood cancer. CAR T-cell therapy is a treatment that changes a person's T-cells (a kind of white blood cell) to better fight cancer. It targets two proteins, CD19 and BCMA, found on myeloma cells. The trial is in two phases: Phase 1b looks at the safety and how the body handles the treatment, and Phase 2 focuses on how well it works.

Eligibility: Participants must be 18 or older, have had at least three previous treatments for Multiple Myeloma, and meet other health criteria. Participants should not have other active cancers or certain heart conditions.

  • The study includes regular health check-ups and may last several months.
  • Participants will receive compensation for their time and travel expenses.
  • Potential risks include side effects from the CAR T-cell therapy.
Print
Study details
    Relapsed/ Refractory Multiple Myeloma

NCT05850234

AstraZeneca

9 August 2025

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Race
Ethnicity
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.